Tonix Pharmaceuticals Holding (TNXP) EBT Margin (2022 - 2026)
Tonix Pharmaceuticals Holding's (TNXP) quarterly EBT Margin came in at 586.44% in Q1 2026, up 6309.0% year-on-year from 9.15% in Q1 2025, and up 32.49% quarter-over-quarter from 868.7% in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) EBT Margin (2022 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's EBT Margin history runs 5 years deep, the most recent figure standing at 586.44% for Q1 2026.
- On a quarterly basis, EBT Margin rose 6309.0% year-over-year to 586.44% in Q1 2026; TTM through Mar 2026 was 839.41%, a 49624.0% increase from a year earlier, with the FY2025 full-year figure at 974.03%, up 100289.0% from the prior year.
- EBT Margin grew to 586.44% in Q1 2026 per TNXP's latest filing, from 868.7% in the prior quarter.
- Across five years, EBT Margin topped out at 509.99% in Q2 2022 and bottomed at 3572.83% in Q2 2024.
- The 5-year median for EBT Margin is 812.0% (2022), against an average of 1003.21%.
- Across the five-year window, EBT Margin tumbled 275048 bps in 2024 and soared 215451 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 801.65% in 2022, then advanced by 12 bps to 709.31% in 2023, then slipped by 23 bps to 873.32% in 2024, then rose by 1 bps to 868.7% in 2025, then jumped by 32 bps to 586.44% in 2026.
- Per Business Quant, the three latest TNXP EBT Margin figures stand at 586.44% (Q1 2026), 868.7% (Q4 2025), and 968.72% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Tonix Pharmaceuticals Holding | 142.07 Mn | 142.07 Mn | 5.30 Mn | -586.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -586.44% |
| Dec 31, 2025 | -868.70% |
| Sep 30, 2025 | -968.72% |
| Jun 30, 2025 | -1,418.32% |
| Mar 31, 2025 | -649.53% |
| Dec 31, 2024 | -873.32% |
| Sep 30, 2024 | -598.83% |
| Jun 30, 2024 | -3,572.83% |
| Mar 31, 2024 | -932.23% |
| Dec 31, 2023 | -709.31% |
| Sep 30, 2023 | -732.74% |
| Jun 30, 2023 | -822.35% |
| Sep 30, 2022 | -801.65% |
| Jun 30, 2022 | -509.99% |